Synergistic activity of gold nanoparticles with amphotericin B on persister cells of Candida tropicalis biofilms.
Candida tropicalis
Amphotericin B
Antibiofilm activity
Gold nanoparticles
Persister cells
Sessile cells
Synergy
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
23
10
2023
accepted:
18
03
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
epublish
Résumé
The antifungal activity was studied on sessile and persister cells (PCs) of Candida tropicalis biofilms of gold nanoparticles (AuNPs) stabilized with cetyltrimethylammonium bromide (CTAB-AuNPs) and those conjugated with cysteine, in combination with Amphotericin B (AmB). The PC model was used and synergistic activity was tested by the checkerboard assay. Biofilms were studied by crystal violet and scanning electron microscopy. After the combination of both AuNPs and AmB the biofilm biomass was reduced, with significant differences in architecture being observed with a reduced biofilm matrix. In addition, the CTAB-AuNPs-AmB combination significantly reduced PCs. Understanding how these AuNPs aid in the fight against biofilms and the development of new approaches to eradicate PCs has relevance for chronic infection treatment.
Identifiants
pubmed: 38755625
doi: 10.1186/s12951-024-02415-6
pii: 10.1186/s12951-024-02415-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
254Subventions
Organisme : Consejo Nacional de Investigaciones Científicas y Técnicas
ID : PIP
Organisme : Consejo Nacional de Investigaciones Científicas y Técnicas
ID : PIP
Organisme : Consejo Nacional de Investigaciones Científicas y Técnicas
ID : PIP
Organisme : Consejo Nacional de Investigaciones Científicas y Técnicas
ID : PIP
Organisme : Consejo Nacional de Investigaciones Científicas y Técnicas
ID : PIP
Organisme : Consejo Nacional de Investigaciones Científicas y Técnicas
ID : PIP
Organisme : Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
ID : 2021
Organisme : Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
ID : 2021
Organisme : Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
ID : 2021
Organisme : Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
ID : 2021
Informations de copyright
© 2024. The Author(s).
Références
WHO fungal. Priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022.
Dos Santos MM, Ishida K. We need to talk about Candida tropicalis: virulence factors and survival mechanisms. Med Mycol. 2023;61(8):myad075.
pubmed: 37505455
doi: 10.1093/mmy/myad075
Malinovská Z, Čonková E, Váczi P. Biofilm formation in medically important Candida species. J Fungi (Basel). 2023;9(10):955.
pubmed: 37888211
doi: 10.3390/jof9100955
de Souza CM, Dos Santos MM, Furlaneto-Maia L, Furlaneto MC. Adhesion and biofilm formation by the opportunistic pathogen Candida tropicalis: what do we know? Can J Microbiol. 2023;69(6):207–18.
pubmed: 36809069
doi: 10.1139/cjm-2022-0195
Defraine V, Fauvart M, Michiels J. Fighting bacterial persistence: current and emerging anti-persister strategies and therapeutics. Drug Resist Updat. 2018;38:12–26.
pubmed: 29857815
doi: 10.1016/j.drup.2018.03.002
Wuyts J, Van Dijck P, Holtappels M. Fungal persister cells: the basis for recalcitrant infections? PLoS Pathog. 2018;14(10):e1007301.
pubmed: 30335865
pmcid: 6193731
doi: 10.1371/journal.ppat.1007301
da Silva MA, Baronetti JL, Páez PL, Paraje MG. Oxidative imbalance in Candida tropicalis biofilms and its relation with persister cells. Front Microbiol. 2021;2:598834.
doi: 10.3389/fmicb.2020.598834
Levin-Reisman I, Brauner A, Ronin I, Balaban NQ. Epistasis between antibiotic tolerance, persistence, and resistance mutations. Proc Natl Acad Sci U S A. 2019;116(29):14734–9.
pubmed: 31262806
pmcid: 6642377
doi: 10.1073/pnas.1906169116
Kaldalu N, Hauryliuk V, Turnbull KJ, La Mensa A, Putrinš M, Tenson T. Vitro studies of persister cells. Microbiol Mol Biol Rev. 2020;84(4):e00070–20.
pubmed: 33177189
pmcid: 7667008
doi: 10.1128/MMBR.00070-20
Gow NAR, Johnson C, Berman J, et al. The importance of antimicrobial resistance in medical mycology. Nat Commun. 2022;13(1):5352.
pubmed: 36097014
pmcid: 9466305
doi: 10.1038/s41467-022-32249-5
Ajetunmobi OH, Badali H, Romo JA, Ramage G, Lopez-Ribot JL. Antifungal therapy of Candida biofilms: past, present and future. Biofilm. 2023;5:100126.
pubmed: 37193227
pmcid: 10182175
doi: 10.1016/j.bioflm.2023.100126
Shrestha L, Fan HM, Tao HR, Huang JD. Recent strategies to combat biofilms using antimicrobial agents and therapeutic approaches. Pathogens. 2022;25(3):292.
doi: 10.3390/pathogens11030292
Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223–7.
pubmed: 19836985
doi: 10.1016/j.riam.2009.06.003
Zhou ZX, Yin XD, Zhang Y, et al. Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database. Front Pharmacol. 2022;13:891336.
pubmed: 35571077
pmcid: 9098189
doi: 10.3389/fphar.2022.891336
Zhang L, Hu Q, Zhang Y, Wang Y, Liu N, Liu Q. Rapid inactivation of mixed biofilms of Candida albicans and Candida tropicalis using antibacterial photodynamic therapy: Based on PAD™ plus. Heliyon e15396 (2023).
Marioni J, Bresolı-Obach R, Agut M, et al. On the mechanism of Candida tropicalis biofilm reduction by the combined action of naturally-occurring anthraquinones and blue light. PLoS ONE. 2017;12:e0181517.
pubmed: 28723923
pmcid: 5517063
doi: 10.1371/journal.pone.0181517
Nasiri K, Masoumi SM, Amini S, et al. Recent advances in metal nanoparticles to treat periodontitis. J Nanobiotechnol. 2023;21(1):283.
doi: 10.1186/s12951-023-02042-7
Lotfali E, Toreyhi H, Makhdoomi Sharabiani K, et al. Comparison of antifungal properties of gold, silver, and selenium nanoparticles against amphotericin B-resistant Candida Glabrata clinical isolates. Avicenna J Med Biotechnol. 2021;13:47–50.
pubmed: 33680373
pmcid: 7903435
da Silva MA, García-Martínez JC, Páez PL, Paraje MG. Fungicidal and antibiofilm activities of gold nanoparticles on Candida tropicalis. Nanomed (Lond). 2022;17(22):1663–76.
doi: 10.2217/nnm-2022-0087
Liu H, Huang Z, Chen H, Zhang Y, Yu P, Hu P, Zhang X, Cao J, Zhou T. A potential strategy against clinical carbapenem-resistant Enterobacteriaceae: antimicrobial activity study of sweetener-decorated gold nanoparticles in vitro and in vivo. J Nanobiotechnol. 2023;6(1):409.
doi: 10.1186/s12951-023-02149-x
Paraje MG. From the magic bullet to nanotechnology: nanoantimicrobials as therapeutics to fight multidrug-resistant microorganisms. Rev Argent Microbiol. 2023;55(3):204–5.
pubmed: 37775252
Marioni J, da SilvaMA, Cabrera JL, Nunez Montoya SC, Paraje MG. The anthraquinones rubiadin and its 1-methyl ether isolated from Heterophyllaea pustulata reduces Candida tropicalis biofilms formation. Phytomedicine. 2016;23:1321–8.
pubmed: 27765351
doi: 10.1016/j.phymed.2016.07.008
Quinteros MA, Galera ILD, Tolosa J, García-Martínez JC, Páez PL, Paraje MG. Novel antifungal activity of oligostyrylbenzenes compounds on Candida tropicalis biofilms. Med Mycol. 2021;59:244–52.
pubmed: 32539092
doi: 10.1093/mmy/myaa046
Kim YG, Garcia-Martinez JC, Crooks RM. Electrochemical properties of monolayer-protected au and pd nanoparticles extracted from within dendrimer templates. Langmuir. 2005;21(12):5485–91.
pubmed: 15924479
doi: 10.1021/la0507582
Garcia-Martinez JC, Crooks RM. Extraction of au nanoparticles having narrow size distributions from within dendrimer templates. J Am Chem Soc. 2004;126(49):16170–8.
pubmed: 15584753
doi: 10.1021/ja046567n
Crespo KA, Baronetti JL, Quinteros MA, Páez PL, Paraje MG. Intra- and extracellular biosynthesis and characterization of iron nanoparticles from prokaryotic microorganisms with anticoagulant activity. Pharm Res. 2017;34:591–8.
pubmed: 27995524
doi: 10.1007/s11095-016-2084-0
Clinical & Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard (4th Edition). Clinical & Laboratory Standards Institute, PA, USA. (2017).
Pierce CG, Uppuluri P, Tristan AR, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc. 2008;3:1494–500.
pubmed: 18772877
pmcid: 2741160
doi: 10.1038/nprot.2008.141
Azeredo J, Azevedo NF, Briandet R, et al. Critical review on biofilm methods. Crit Rev Microbiol. 2017;43(3):313–51.
pubmed: 27868469
doi: 10.1080/1040841X.2016.1208146
Thieme L, Hartung A, Tramm K, et al. MBEC Versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology. Biol Proced Online. 2019;21:18.
pubmed: 31528123
pmcid: 6743098
doi: 10.1186/s12575-019-0106-0
Van Dijck P, Sjollema J, Cammue BP, et al. Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microb Cell. 2018;5(7):300–26.
pubmed: 29992128
pmcid: 6035839
doi: 10.15698/mic2018.07.638
Al-Dhaheri RS, Douglas LJ. Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species. Antimicrob Agents Chemother. 2008;52:1884–7.
pubmed: 18285487
pmcid: 2346666
doi: 10.1128/AAC.01473-07
De Brucker K, De Cremer K, Cammue BP, Thevissen K. Protocol for determination of the persister subpopulation in Candida albicans biofilms. Methods Mol Biol. 2016;1333:67–72.
pubmed: 26468100
doi: 10.1007/978-1-4939-2854-5_6
Lohse MB, Gulati M, Craik CS, Johnson AD, Nobile CJ. Combination of antifungal drugs and protease inhibitors prevent Candida albicans biofilm formation and disrupt mature biofilms. Front Microbiol. 2020;11:1027.
pubmed: 32523574
pmcid: 7261846
doi: 10.3389/fmicb.2020.01027
Schwarz P, Nikolskiy I, Bidaud A-L, Sommer F, Bange G, Dannaoui E. In Vitro synergy of isavuconazole combined with colistin against common Candida species. Front Cell Infect Microbiol. 2022;12:892893.
pubmed: 35573795
pmcid: 9100415
doi: 10.3389/fcimb.2022.892893
Bidaud AL, Schwarz P, Herbreteau G, Dannaoui E. Techniques for the assessment of in vitro and in vivo antifungal combinations. J Fungi (Basel). 2021;7(2):113.
pubmed: 33557026
doi: 10.3390/jof7020113
Fuentealba-Manosalva O, Mansilla M, Buelvas N, Martin-Martin A, Torres CG, López-Muñoz RA. Mind the curve: dose-response fitting biases the synergy scores across software used for chemotherapy combination studies. Int J Mol Sci. 2023;3(11):9705.
doi: 10.3390/ijms24119705
Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;15(18):2866–8.
doi: 10.1093/bioinformatics/btw230
Lara HH, Romero-Urbina DG, Pierce C, Lopez-Ribot JL, Arellano-Jiménez MJ, Jose-Yacaman M. Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study. J Nanobiotech. 2015;15:13:91.
doi: 10.1186/s12951-015-0147-8
Caldeirão ACM, Araujo HC, Arias LS, Ramírez Carmona W, Miranda GP, Oliveira SHP, Pessan JP, Monteiro DR. Nanocarriers of miconazole or fluconazole: effects on three-sspecies Candida biofilms and cytotoxic effects in vitro. J Fungi (Basel) 23;7(7):500 (2021)
Chee E, García AJ. Biomaterial therapeutic strategies for treatment of bacterial lung infections. Biofilm. 2023;5:100111.
pubmed: 36909663
pmcid: 9999167
doi: 10.1016/j.bioflm.2023.100111
de Alteriis E, Maselli V, Falanga A, et al. Efficiency of gold nanoparticles coated with the antimicrobial peptide indolicidin against biofilm formation and development of Candida spp. clinical isolates. Infect Drug Resist. 2018;11:915–25.
pubmed: 30013374
pmcid: 6037145
doi: 10.2147/IDR.S164262
Carmo PHFD, Garcia MT, Figueiredo-Godoi LMA, Lage ACP, Silva NSD, Junqueira JC. Metal nanoparticles to combat Candida albicans infections: an update. Microorganisms. 2023;11(1):138.
pubmed: 36677430
pmcid: 9861183
doi: 10.3390/microorganisms11010138
Wambaugh MA, Denham ST, Ayala M, Brammer B, Stonhill MA, Brown JC. Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. Elife. 2020;9:e54160.
pubmed: 32367801
pmcid: 7200157
doi: 10.7554/eLife.54160
Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14:320–30.
pubmed: 27080241
doi: 10.1038/nrmicro.2016.34
Sun J, Li Z, Chu H, Guo J, Jiang G, Qi Q. Candida albicans amphotericin B-tolerant persister formation is closely related to surface adhesion. Mycopathologia. 2016;181(1–2):41–9.
pubmed: 26381156
doi: 10.1007/s11046-015-9894-1
Vazquez-Munoz R, Lopez FD, Lopez-Ribot JL. Silver nanoantibiotics display strong antifungal activity against the emergent multidrug-resistant yeast Candida Auris under both planktonic and biofilm growing conditions. Front Microbiol. 2020;11:1673.
pubmed: 32849347
pmcid: 7399222
doi: 10.3389/fmicb.2020.01673
Okkeh M, Bloise N, Restivo E, De Vita L, Pallavicini P, Visai L. Gold nanoparticles: can they be the next magic bullet for multidrug-resistant bacteria? Nanomaterials (Basel). 2021;11(2):312.
pubmed: 33530434
doi: 10.3390/nano11020312
Baptista PV, McCusker MP, Carvalho A, et al. Nano-strategies to fight multidrug resistant bacteria-A battle of the titans. Front Microbiol. 2018;9:1441.
pubmed: 30013539
pmcid: 6036605
doi: 10.3389/fmicb.2018.01441
Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther 10(1), 115–47.
Díaz de León-Ortega R, D’Arcy DM, Fotaki N. In vitro conditions for performance evaluation of products for intravascular administration: developing appropriate test media using amphotericin B as a model drug. Eur J Pharm Sci. 2020;143:105174.
pubmed: 31809909
doi: 10.1016/j.ejps.2019.105174
Manosroi A, Kongkaneramit L, Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int J Pharm. 2004;270(1–2):279–86.
pubmed: 14726142
doi: 10.1016/j.ijpharm.2003.10.031
Faustino C, Serafim C, Ferreira I, Pinheiro L, Calado A. Solubilization power of an amino acid-based gemini surfactant towards the hydrophobic drug amphotericin B. Colloids Surf Physicochem Eng Asp. 2015;480:426–32.
doi: 10.1016/j.colsurfa.2014.11.039
Te Dorsthorst DT, Verweij PE, Meletiadis J, Bergervoet M, Punt NC, Meis JF, Mouton JW. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother. 2002;46(9):2982–9.
pubmed: 12183257
pmcid: 127432
doi: 10.1128/AAC.46.9.2982-2989.2002
Weis MR, Levine HB. Inactivation of amphotericin B by reducing agents: influences on growth inhibition of Candida albicans and lysis of erythrocytes. Med Mycol. 1972;10(2):132–42.
doi: 10.1080/00362177285190271